Literature DB >> 22535992

Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.

Rachel R Higgins1, Melissa Beniprashad, Eddie Chong-King, Yan Li, Nathalie Bastien, Donald E Low, Jonathan B Gubbay.   

Abstract

The H275Y oseltamivir resistance mutation confers high-level resistance to oseltamivir in isolates of human A(H1N1) influenza. We report the recovery and identification of an influenza B virus with the H273Y neuraminidase point mutation directly from a human patient. The H273Y influenza B isolate is resistant to oseltamivir and peramivir but sensitive to zanamivir.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22535992      PMCID： PMC3405592          DOI： 10.1128/JCM.00682-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Global transmission of oseltamivir-resistant influenza.

Authors:  Anne Moscona
Journal:  N Engl J Med       Date:  2009-03-02       Impact factor: 91.245

2.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

3.  Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.

Authors:  Margaret Okomo-Adhiambo; Gail J Demmler-Harrison; Varough M Deyde; Tiffany G Sheu; Xiyan Xu; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

4.  Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.

Authors:  Yacine Abed; Mariana Baz; Guy Boivin
Journal:  Antivir Ther       Date:  2006

5.  Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.

Authors:  Tatiana Baranovich; Reiko Saito; Yasushi Suzuki; Hassan Zaraket; Clyde Dapat; Isolde Caperig-Dapat; Taeko Oguma; Iman Ibrahim Shabana; Takehiko Saito; Hiroshi Suzuki
Journal:  J Clin Virol       Date:  2009-12-03       Impact factor: 3.168

6.  Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing.

Authors:  Tiffany G Sheu; Varough M Deyde; Rebecca J Garten; Alexander I Klimov; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2009-11-01       Impact factor: 5.970

7.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

8.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.

Authors:  Patrick J Collins; Lesley F Haire; Yi Pu Lin; Junfeng Liu; Rupert J Russell; Philip A Walker; John J Skehel; Stephen R Martin; Alan J Hay; Steven J Gamblin
Journal:  Nature       Date:  2008-05-14       Impact factor: 49.962

9.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.

Authors:  Nila J Dharan; Larisa V Gubareva; John J Meyer; Margaret Okomo-Adhiambo; Reginald C McClinton; Steven A Marshall; Kirsten St George; Scott Epperson; Lynnette Brammer; Alexander I Klimov; Joseph S Bresee; Alicia M Fry
Journal:  JAMA       Date:  2009-03-02       Impact factor: 56.272

10.  Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

Authors:  Arnold S Monto; Jennifer L McKimm-Breschkin; Catherine Macken; Alan W Hampson; Alan Hay; Alexander Klimov; Masato Tashiro; Robert G Webster; Michelle Aymard; Frederick G Hayden; Maria Zambon
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191
View more
  7 in total

Review 1.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

2.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.

Authors:  Andrew J Burnham; Jianling Armstrong; Anice C Lowen; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

Review 4.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections.

Authors:  Malak M Alame; Elie Massaad; Hassan Zaraket
Journal:  Front Microbiol       Date:  2016-03-31       Impact factor: 5.640

6.  Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Authors:  Margaret Okomo-Adhiambo; Katrina Sleeman; Colleen Lysén; Ha T Nguyen; Xiyan Xu; Yan Li; Alexander I Klimov; Larisa V Gubareva
Journal:  Influenza Other Respir Viruses       Date:  2013-04-10       Impact factor: 4.380

7.  Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.

Authors:  R Farrukee; A E Zarebski; J M McCaw; J D Bloom; P C Reading; A C Hurt
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.